Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial

PURPOSE: Considerable molecular heterogeneity exists among human epidermal growth factor receptor 2 (HER2) –positive breast cancer regarding gene expression and mutation profiling. Evidence from preclinical, clinical neoadjuvant, and metastatic clinical trials suggested that PIK3CA mutational status...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Pogue-Geile, Katherine L., Song, Nan, Jeong, Jong-Hyeon, Gavin, Patrick G., Kim, Seong-Rim, Blackmon, Nicole L., Finnigan, Melanie, Rastogi, Priya, Fehrenbacher, Louis, Mamounas, Eleftherios P., Swain, Sandra M., Wickerham, D. Lawrence, Geyer, Charles E., Costantino, Joseph P., Wolmark, Norman, Paik, Soonmyung
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2015
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4397278/
https://ncbi.nlm.nih.gov/pubmed/25559813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.2439
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares